| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP Process Dev, Manufacturing
1 company
Paul Sauer last filed a Form 4 in December 2022, as SVP Process Dev, Manufacturing at PCVX. From January 2021 to September 2022, the filings on record show 0 open-market purchases and 13 sales. Paul Sauer's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Paul Sauer's trades have earned a below-average insider score of 43/100 across 11 rated trades. Over a 12-month horizon, 18.2% of those trades were profitable, with an average 12-month return of -63.8%.
At the last filing, the largest reported position was 13,822 shares of PCVX. The PCVX filings lean toward selling, a net 45,807 shares.
Shares as reported in the last Form 4 for each company; the most recent is from December 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2021 | PCVX Vaxcyte, Inc. | SVP Process Dev, Manufacturing | Sale+OE | 2,500 | $25.00 | $62,500.00 | -3.1% | -13.6% | -10.3% | |
| Feb 11, 2021 | PCVX Vaxcyte, Inc. | SVP Process Dev, Manufacturing | Sale+OE | 2,500 | $26.65 | $66,624.36 | -3.1% | - | - | |
| Jan 11, 2021 | PCVX Vaxcyte, Inc. | SVP Process Dev, Manufacturing | Sale+OE | 2,500 | $26.21 | $65,526.72 | -3.1% | - | - |